Caring for Patients With EGFR-Positive Non−Small Cell Lung Cancer: An Interactive Review of New Drug Therapies Targeting Exon 20 Insertion Mutations

This activity includes animation videos.

This activity was originally broadcast live at the 2022 Asembia Specialty Pharmacy Summit.

Program Description

Improvements in screening techniques and advancements in therapy have improved prognosis and overall survival for patients with non-small cell lung cancer (NSCLC). Identification of specific biomarkers in NSCLC such as epidermal growth factor receptor (EGFR) mutations has become central in treatment selection and expanded utilization of targeted agents including EGFR-targeted tyrosine kinase inhibitors (TKIs). However, one challenge with use of TKIs is development of resistance. With several EGFR-TKIs recently approved and under investigation for the treatment of NSCLC, oncology pharmacists on the multidisciplinary care team must be familiar with characteristics of these therapies targeting exon 20 insertion mutations. While the emergence of EGFR TKIs has positively altered the landscape for EGFR positive NSCLC, pharmacists need to be cognizant of the risks associated with these treatments and intervene to reduce these risks and improve overall outcomes. Faculty experts will review patient cases highlighting important counseling points regarding management of adverse effects of EGFR-TKI therapy.

Target audience: Health system pharmacists, oncology pharmacists, and specialty pharmacist

Type of activity: Application
Release date: June 14, 2022
Expiration date: June 14, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore the role of EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC) and the challenges associated with historic systemic treatment options
• Identify specific characteristics of systemic therapies targeting exon 20 insertion mutations in EGFR-positive NSCLC that specialty pharmacists should consider for patient counseling sessions
• Construct a plan for the onboarding and follow-up of a patient receiving treatment for EGFR-positive NSCLC with a novel exon 20 insertion mutation-targeting agent

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-301-H01-P. The activity is available for CE credit through June 14, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Jeff Engle, PharmD, MS has the following financial relationships with commercial interests to disclose: Consultant: Ad Boards for Lilly; Beigene; Janssen. Speaker’s Bureau: Eisai Inc; Lilly Oncology; Amgen.  

Stefanie L. Houseknecht, PharmD, BCOP has no financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms